共 5 条
[1]
Observational 24-week study to assess clinical response to upadacitinib posttrial in patients with moderate-to-severe atopic dermatitis
[J].
JEADV CLINICAL PRACTICE,
2023, 2 (03)
:571-575
[2]
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
[J].
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,
2023, 89 (03)
:478-485